Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma
FDA Grants Priority Review for KEYTRUDA® and KEYTRUDA QLEX , Each with Padcev® , for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
European Commission Approves Merck's ENFLONSIA for the Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants During Their First RSV Season
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 , an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
European Commission Approves KEYTRUDA® Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins
Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
QIMC Announces Closing of $17.3 Million Bought Deal Offering, Including Full Exercise of Underwriter's Over-Allotment Option
New Found Gold Closes Bought Deal Financing Including Full Exercise of Underwriters' Over-Allotment Option for Gross Proceeds of $115M
Couloir Capital Is Pleased to Announce That It Has Initiated Research Coverage on Pinnacle Silver and Gold
Corcel Exploration Reports Positive Results from an Induced Polarization Survey at Yuma King, Arizona
